A 35-year-old male from rural Maharashtra with a 3-month history of cough and fever presents to a primary health centre. Sputum smear microscopy is positive for acid-fast bacilli. Which is the most common drug-resistant pattern observed in newly diagnosed tuberculosis patients in India?

Explanation

## Drug Resistance Patterns in Indian TB Epidemiology **Key Point:** Isoniazid (INH) monoresistance is the most common drug-resistant pattern in newly diagnosed TB patients in India, occurring in approximately 3–5% of new TB cases, followed by MDR-TB at 2–3%. ### Prevalence of Drug Resistance in India (New TB Cases) | Resistance Pattern | Prevalence (%) | Clinical Significance | |-------------------|----------------|----------------------| | **Isoniazid monoresistance** | 3–5 | Most common; standard regimen still effective (RIF carries the load) | | MDR-TB (INH + RIF) | 2–3 | Requires longer, more toxic second-line therapy | | Rifampicin monoresistance | <1 | Rare; usually indicates INH resistance as well | | XDR-TB (MDR + FQ + injectable) | <0.5 | Extremely rare in new cases; mostly in treated patients | | Pan-susceptible TB | 90–95 | Majority of TB cases remain drug-susceptible | **High-Yield:** India's TB epidemiology (2023 data): - ~27 million TB cases estimated globally; India accounts for ~27% (highest burden) - MDR-TB burden: ~130,000 cases annually (highest globally) - However, in **newly diagnosed** (treatment-naive) patients, INH monoresistance > MDR-TB - INH monoresistance is often due to *katG* or *inhA* gene mutations ### Why INH Monoresistance Is Most Common in New Cases 1. **Lower selective pressure:** INH monoresistance emerges more easily than MDR-TB in drug-susceptible populations 2. **Mutation rate:** Single mutations conferring INH resistance occur at ~10^−6^ per bacillus; MDR requires two independent mutations 3. **Clinical outcome:** INH monoresistant TB still responds well to standard RIPE regimen because RIF is the most potent agent 4. **Epidemiological pattern:** INH monoresistance is often detected incidentally on drug susceptibility testing (DST); many patients are treated successfully without knowing the resistance pattern **Clinical Pearl:** In a newly diagnosed TB patient with INH monoresistance: - Standard 4-drug regimen (RIPE) is still effective - No change in treatment required if DST not available - Cure rates remain >90% with standard therapy - Contrast with MDR-TB, which requires 20-month second-line regimen **Mnemonic:** **"INH before MDR"** — In newly diagnosed TB patients, single-drug resistance (especially INH) is more common than multidrug resistance. This reflects the natural progression of resistance development. [cite:Park 26e Ch 7]